Literature DB >> 23568852

Modeling trajectories of regional volume loss in progressive supranuclear palsy.

Keith A Josephs1, Rong Xia, Jay Mandrekar, Jeffrey L Gunter, Matthew L Senjem, Clifford R Jack, Jennifer L Whitwell.   

Abstract

Progressive supranuclear palsy is a neurodegenerative disease with progressive brain atrophy over time. It is unknown which specific brain regions decline over time, whether regional volume loss occurs in a linear fashion, and whether regional atrophy correlates with clinical decline over time in progressive supranuclear palsy. Twenty-eight subjects meeting probable progressive supranuclear palsy criteria were prospectively recruited and completed 96 MRI scans over 2 years. Mixed-effect models were utilized to determine which regions had significant atrophy over time and whether decline was linear or nonlinear. We assessed 13 regions across the brain, as well as whole-brain and ventricular volume. Regional trajectories were also correlated with change in clinical measures of executive function and gait and ocular motor impairment. A linear decline was observed in all frontal and temporal regions, the superior parietal lobe, the thalamus, the caudate nuclei, and the midbrain, as well as in the whole brain. Ventricular expansion was also linear. Nonlinear decline was observed for the caudal middle frontal lobe and globus pallidus. Rates of change in the superior frontal lobe, thalamus, and midbrain were beyond those expected in normal aging. Decline in frontal lobe volume and the midbrain area correlated best to decline in clinical measures. In progressive supranuclear palsy, atrophy is occurring in multiple brain regions, particularly in those that have previously been implicated in the disease. Decline is mainly linear but can be nonlinear for some regions. The frontal lobe and midbrain seem to be playing the most significant roles in the progressive worsening of clinical signs in progressive supranuclear palsy.
Copyright © 2013 Movement Disorder Society.

Entities:  

Keywords:  PSP; longitudinal; midbrain; mixed-effects models; rates

Mesh:

Year:  2013        PMID: 23568852     DOI: 10.1002/mds.25437

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  20 in total

1.  The evolution of primary progressive apraxia of speech.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Jeffrey L Gunter; Christopher G Schwarz; Robert I Reid; Anthony J Spychalla; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Brain       Date:  2014-08-11       Impact factor: 13.501

Review 2.  Key emerging issues in progressive supranuclear palsy and corticobasal degeneration.

Authors:  Keith A Josephs
Journal:  J Neurol       Date:  2015-02-21       Impact factor: 4.849

3.  Multimodal neuroimaging relationships in progressive supranuclear palsy.

Authors:  Irene Sintini; Christopher G Schwarz; Matthew L Senjem; Robert I Reid; Hugo Botha; Farwa Ali; J Eric Ahlskog; Clifford R Jack; Val J Lowe; Keith A Josephs; Jennifer L Whitwell
Journal:  Parkinsonism Relat Disord       Date:  2019-07-02       Impact factor: 4.891

4.  Neuropsychiatric symptoms in primary progressive aphasia and apraxia of speech.

Authors:  Tarun D Singh; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Jennifer L Whitwell; Keith A Josephs
Journal:  Dement Geriatr Cogn Disord       Date:  2015-01-21       Impact factor: 2.959

5.  Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Authors:  Tien Dam; Adam L Boxer; Lawrence I Golbe; Günter U Höglinger; Huw R Morris; Irene Litvan; Anthony E Lang; Jean-Christophe Corvol; Ikuko Aiba; Michael Grundman; Lili Yang; Beth Tidemann-Miller; Joseph Kupferman; Kristine Harper; Kubra Kamisoglu; Michael J Wald; Danielle L Graham; Liz Gedney; John O'Gorman; Samantha Budd Haeberlein
Journal:  Nat Med       Date:  2021-08-12       Impact factor: 87.241

6.  Concurrent brain structural and functional alterations in patients with chronic unilateral vestibulopathy.

Authors:  Lihong Si; Bin Cui; Zheyuan Li; Xiang Li; Kangzhi Li; Xia Ling; Bo Shen; Xu Yang
Journal:  Quant Imaging Med Surg       Date:  2022-06

7.  Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.

Authors:  Richard M Tsai; Iryna Lobach; Jee Bang; Jennifer L Whitwell; Matthew L Senjem; Clifford R Jack; Howard Rosen; Bruce Miller; Adam L Boxer
Journal:  Parkinsonism Relat Disord       Date:  2016-04-24       Impact factor: 4.891

8.  Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

Authors:  Adam L Boxer; Anthony E Lang; Murray Grossman; David S Knopman; Bruce L Miller; Lon S Schneider; Rachelle S Doody; Andrew Lees; Lawrence I Golbe; David R Williams; Jean-Cristophe Corvol; Albert Ludolph; David Burn; Stefan Lorenzl; Irene Litvan; Erik D Roberson; Günter U Höglinger; Mary Koestler; Clifford R Jack; Viviana Van Deerlin; Christopher Randolph; Iryna V Lobach; Hilary W Heuer; Illana Gozes; Lesley Parker; Steve Whitaker; Joe Hirman; Alistair J Stewart; Michael Gold; Bruce H Morimoto
Journal:  Lancet Neurol       Date:  2014-05-27       Impact factor: 44.182

Review 9.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Authors:  Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs
Journal:  Mov Disord       Date:  2017-05-13       Impact factor: 10.338

10.  Progression of brain atrophy in PSP and CBS over 6 months and 1 year.

Authors:  Shubir Dutt; Richard J Binney; Hilary W Heuer; Phi Luong; Suneth Attygalle; Priyanka Bhatt; Gabe A Marx; Jonathan Elofson; Maria C Tartaglia; Irene Litvan; Scott M McGinnis; Bradford C Dickerson; John Kornak; Dana Waltzman; Lisa Voltarelli; Norbert Schuff; Gil D Rabinovici; Joel H Kramer; Clifford R Jack; Bruce L Miller; Howard J Rosen; Adam L Boxer
Journal:  Neurology       Date:  2016-10-14       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.